Full-Time

Senior Director Global Regulatory Lead

Immunome

Immunome

201-500 employees

Antibody-based therapeutic discovery and development

Compensation Overview

$226k - $270k/yr

Washington, USA

Hybrid

Monthly travel to Bothell, Washington required.

Category
Legal & Compliance (1)
Required Skills
Risk Management

Get referred to Immunome

See people who can refer or advise you

Requirements
  • Bachelor’s degree in relevant scientific discipline
  • A minimum of 10 years of experience in global regulatory affairs in the pharmaceutical/biotechnology industry, or equivalent experience
  • Proven success in leading regulatory submissions and obtaining approvals in major markets
  • Experience developing oncology therapeutics is strongly preferred
  • Ability to travel monthly to Bothell, Washington headquarters
  • Direct experience leading regulatory submissions, health authority meetings and interactions with in-depth knowledge of the internal operations and outlook of the FDA, EMA and other global health authorities
  • Has a comprehensive and disciplined approach to regulatory risk management and compliance through deep expertise and understanding of the oncology therapeutic area
  • Highly collaborative self-starter and team player who fosters open communication and facilitates mutual understanding and cooperation between all stakeholders
  • Outstanding communication, analytical, organizational and time management skills
  • Experience and passion to work with small teams, ability to work comfortably under pressure under evolving scenarios and tight deadlines
  • Detail-minded yet flexible work style; manage multiple projects and timelines simultaneously, and rapidly change priorities based on business needs
Responsibilities
  • Define and implement global regulatory strategies that adapt to changing regulatory and business needs
  • Communicate key developments to project teams and stakeholders, ensuring alignment and sound judgment
  • Anticipate risks and devise solutions, understanding the likelihood of technical success for proposed strategies
  • Lead the Global Regulatory Team, fostering a high-performance culture through coaching and mentoring
  • Collaborate with regional regulatory leads and vendors to ensure compliance with local regulations for global submissions
  • Communicate effectively with internal and external partners, advocating for regulatory positions in governance and cross-functional committees
  • Identify regulatory risks and opportunities, developing strategies to mitigate risks and enhance success rates
  • Ensure timely preparation and submission of regulatory submissions (e.g., INDs, BLAs, NDAs) while maintaining compliance with regional and global requirements
  • Act as the primary contact with global health authorities and lead FDA meetings
  • Monitor industry trends and regulatory changes, adapting strategies to mitigate impacts on product development
Desired Qualifications
  • Experience developing oncology therapeutics is strongly preferred

Immunome identifies antibodies and their targets by studying the immune systems of patients who recover from diseases, to develop first-in-class therapeutics. Its platform analyzes immune responses to discover novel antibodies and their targets, which are then advanced through research and development in partnership with healthcare and medical research clients. The company’s products work by using antibodies discovered from patients’ immune systems to target diseases, potentially enabling new treatments across oncology and other areas. Immunome differentiates itself through a proprietary discovery platform that extracts clinically relevant antibodies from real patient immune responses, enabling collaborations and licensing deals rather than solely pursuing standalone drug sales. The goal is to bring new antibody therapies to patients by forming partnerships, licensing innovations, and eventually delivering approved therapies.

Company Size

201-500

Company Stage

IPO

Headquarters

Bothell, Washington

Founded

2008

Get referred to Immunome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Varegacestat’s NDA could create near-term commercial revenue from desmoid tumors.
  • IM-1617’s first-in-human study offers a catalyst in immune-excluding solid tumors.
  • IM-1021 can validate HC74 safety and pharmacokinetics for follow-on ADCs.

What critics are saying

  • IM-1617’s undisclosed target raises validation risk if patient data disappoint.
  • HC74 toxicity in IM-1021 would damage the broader ADC pipeline.
  • Immunome still depends on capital markets until approved products generate cash.

What makes Immunome unique

  • Immunome’s Discovery Engine mines human memory B cells from disease-surviving patients.
  • The company focuses on first-in-class and best-in-class targeted oncology therapies.
  • Its HC74 payload platform supports multiple ADC programs across distinct targets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Hybrid Work Options

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

21%

1 year growth

21%

2 year growth

9%
Yahoo Finance
Apr 4th, 2026
Immunome CSO sells $204K in shares ahead of Q2 2026 NDA submission

Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares on 2 April for $204,238, reducing his direct holdings by 30% to 22,000 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025 for financial diversification. The transaction comes as the clinical-stage biotechnology company approaches a significant milestone: its lead candidate varegacestat met the primary endpoint in a Phase 3 trial in December 2025, with an FDA submission planned for the second quarter of 2026. Immunome expects three additional investigational new drug applications and early data from IM-1021 across 2026. The company's stock has risen 250% over the past year, bringing its market capitalisation to $2.40 billion.

Yahoo Finance
Mar 6th, 2026
Immunome cuts 2025 net loss to $212M, files $156M shelf registration ahead of varegacestat NDA

Immunome has reported a reduced full-year net loss of $212.39 million for 2025 and filed a $156.03 million common stock shelf registration linked to an employee stock option plan offering. The biotechnology company also updated investors on progress in its oncology pipeline. The company plans to file a New Drug Application for varegacestat following positive Phase 3 data, with multiple solid tumour investigational new drug applications also in development. However, Immunome remains deeply unprofitable despite the narrower losses. The shelf registration raises concerns about potential equity dilution and ownership overhang. Fair value estimates from analysts vary widely, ranging from approximately $29 to over $215 per share, reflecting significant uncertainty around the company's prospects as it advances its high-risk oncology platform.

ChartMill
Jan 6th, 2026
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Immunome to present at 44th Annual J.P. Morgan Healthcare Conference. Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome's website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260106254447/en/

Business Wire
Dec 18th, 2025
Immunome Announces Pricing of Public Offering of Common Stock

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today a...

Business Wire
Feb 1st, 2025
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies,